Suppr超能文献

调节细胞内途径以改善 RNA 治疗药物的非病毒递送。

Modulating intracellular pathways to improve non-viral delivery of RNA therapeutics.

机构信息

Ghent Research Group on Nanomedicines, Laboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium.

出版信息

Adv Drug Deliv Rev. 2022 Feb;181:114041. doi: 10.1016/j.addr.2021.114041. Epub 2021 Nov 8.

Abstract

RNA therapeutics (e.g. siRNA, oligonucleotides, mRNA, etc.) show great potential for the treatment of a myriad of diseases. However, to reach their site of action in the cytosol or nucleus of target cells, multiple intra- and extracellular barriers have to be surmounted. Several non-viral delivery systems, such as nanoparticles and conjugates, have been successfully developed to meet this requirement. Unfortunately, despite these clear advances, state-of-the-art delivery agents still suffer from relatively low intracellular delivery efficiencies. Notably, our current understanding of the intracellular delivery process is largely oversimplified. Gaining mechanistic insight into how RNA formulations are processed by cells will fuel rational design of the next generation of delivery carriers. In addition, identifying which intracellular pathways contribute to productive RNA delivery could provide opportunities to boost the delivery performance of existing nanoformulations. In this review, we discuss both established as well as emerging techniques that can be used to assess the impact of different intracellular barriers on RNA transfection performance. Next, we highlight how several modulators, including small molecules but also genetic perturbation technologies, can boost RNA delivery by intervening at differing stages of the intracellular delivery process, such as cellular uptake, intracellular trafficking, endosomal escape, autophagy and exocytosis.

摘要

RNA 疗法(例如 siRNA、寡核苷酸、mRNA 等)在治疗多种疾病方面具有巨大的潜力。然而,为了使其在靶细胞的细胞质或细胞核中发挥作用,必须克服多个细胞内和细胞外的障碍。已经成功开发了几种非病毒递送系统,如纳米颗粒和缀合物,以满足这一要求。不幸的是,尽管取得了这些明显的进展,但最先进的递送剂仍然存在相对较低的细胞内递送效率。值得注意的是,我们目前对细胞内递药过程的理解在很大程度上过于简单化。深入了解 RNA 制剂如何被细胞加工,将为下一代递药载体的合理设计提供动力。此外,确定哪些细胞内途径有助于有效的 RNA 递药,可能为提高现有纳米制剂的递药性能提供机会。在这篇综述中,我们讨论了可用于评估不同细胞内障碍对 RNA 转染性能影响的既定和新兴技术。接下来,我们强调了几种调节剂(包括小分子,但也包括遗传扰动技术)如何通过干预细胞内递药过程的不同阶段(如细胞摄取、细胞内转运、内体逃逸、自噬和胞吐)来提高 RNA 递药效率。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验